Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

BibTeX

@article{allodium:10.1016/j.lanepe.2023.100613,
  title = {Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial},
  author = {Júlia Corominas and Carme Garriga and Antoni Prenafeta and Alexandra Moros and Manuel Cañete and Antonio Barreiro and Luis González-González and Laia Madrenas and Irina Güell and Bonaventura Clotet and Nuria Izquierdo-Useros and Dàlia Raïch-Regué and Marçal Gallemí and Julià Blanco and Edwards Pradenas and Benjamin Trinité and Julia G. Prado and Oscar Blanch-Lombarte and Raúl Pérez-Caballero and Montserrat Plana and Ignasi Esteban and Carmen Pastor-Quiñones and Xavier Núñez-Costa and Rachel Abu Taleb and Paula McSkimming and Alex Soriano and Jocelyn Nava and Jesse Omar Anagua and Rafel Ramos and Ruth Martí Lluch and Aida Corpes Comes and Susana Otero Romero and Xavier Martinez Gomez and Carla Sans-Pola and José Moltó and Susana Benet and Lucía Bailón and Jose R. Arribas and Alberto M. Borobia and Javier Queiruga Parada and Jorge Navarro-Pérez and Maria José Forner Giner and Rafael Ortí Lucas and María del Mar Vázquez Jiménez and Salvador Oña Compán and Melchor Alvarez-Mon and Daniel Troncoso and Eunate Arana-Arri and Susana Meijide and Natale Imaz-Ayo and Patricia Muñoz García and Sofía de la Villa Martínez and Sara Rodríguez Fernández and Teresa Prat and Èlia Torroella and Laura Ferrer},
  year = {2023},
  journal = {The Lancet Regional Health - Europe},
  doi = {10.1016/j.lanepe.2023.100613},
  url = {https://doi.org/10.1016/j.lanepe.2023.100613}
}

RIS

TY  - JOUR
TI  - Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
AU  - Júlia Corominas
AU  - Carme Garriga
AU  - Antoni Prenafeta
AU  - Alexandra Moros
AU  - Manuel Cañete
AU  - Antonio Barreiro
AU  - Luis González-González
AU  - Laia Madrenas
AU  - Irina Güell
AU  - Bonaventura Clotet
AU  - Nuria Izquierdo-Useros
AU  - Dàlia Raïch-Regué
AU  - Marçal Gallemí
AU  - Julià Blanco
AU  - Edwards Pradenas
AU  - Benjamin Trinité
AU  - Julia G. Prado
AU  - Oscar Blanch-Lombarte
AU  - Raúl Pérez-Caballero
AU  - Montserrat Plana
AU  - Ignasi Esteban
AU  - Carmen Pastor-Quiñones
AU  - Xavier Núñez-Costa
AU  - Rachel Abu Taleb
AU  - Paula McSkimming
AU  - Alex Soriano
AU  - Jocelyn Nava
AU  - Jesse Omar Anagua
AU  - Rafel Ramos
AU  - Ruth Martí Lluch
AU  - Aida Corpes Comes
AU  - Susana Otero Romero
AU  - Xavier Martinez Gomez
AU  - Carla Sans-Pola
AU  - José Moltó
AU  - Susana Benet
AU  - Lucía Bailón
AU  - Jose R. Arribas
AU  - Alberto M. Borobia
AU  - Javier Queiruga Parada
AU  - Jorge Navarro-Pérez
AU  - Maria José Forner Giner
AU  - Rafael Ortí Lucas
AU  - María del Mar Vázquez Jiménez
AU  - Salvador Oña Compán
AU  - Melchor Alvarez-Mon
AU  - Daniel Troncoso
AU  - Eunate Arana-Arri
AU  - Susana Meijide
AU  - Natale Imaz-Ayo
AU  - Patricia Muñoz García
AU  - Sofía de la Villa Martínez
AU  - Sara Rodríguez Fernández
AU  - Teresa Prat
AU  - Èlia Torroella
AU  - Laura Ferrer
PY  - 2023
JO  - The Lancet Regional Health - Europe
DO  - 10.1016/j.lanepe.2023.100613
UR  - https://doi.org/10.1016/j.lanepe.2023.100613
ER  - 

APA

Corominas, J., Garriga, C., Prenafeta, A., Moros, A., Cañete, M., Barreiro, A., González-González, L., Madrenas, L., Güell, I., Clotet, B., Izquierdo-Useros, N., Raïch-Regué, D., Gallemí, M., Blanco, J., Pradenas, E., Trinité, B., Prado, J. G., Blanch-Lombarte, O., Pérez-Caballero, R., Plana, M., Esteban, I., Pastor-Quiñones, C., Núñez-Costa, X., Taleb, R. A., McSkimming, P., Soriano, A., Nava, J., Anagua, J. O., Ramos, R., Lluch, R. M., Comes, A. C., Romero, S. O., Gomez, X. M., Sans-Pola, C., Moltó, J., Benet, S., Bailón, L., Arribas, J. R., Borobia, A. M., Parada, J. Q., Navarro-Pérez, J., Giner, M. J. F., Lucas, R. O., Jiménez, M. D. M. V., Compán, S. O., Alvarez-Mon, M., Troncoso, D., Arana-Arri, E., Meijide, S., Imaz-Ayo, N., García, P. M., Martínez, S. D. L. V., Fernández, S. R., Prat, T., Torroella, È., & Ferrer, L. (2023). Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. The Lancet Regional Health - Europe. https://doi.org/10.1016/j.lanepe.2023.100613